Markets

World Precision Drugs Software program Market to Attain $2.6 Billion by 2027

Summary: – World Precision Drugs Software program Market to Attain $2. 6 Billion by 2027. – Amid the COVID-19 disaster, the worldwide marketplace for Precision Drugs Software program estimated at US$1.

New York, July 07, 2021 (GLOBE NEWSWIRE) — Reportlinker.com declares the discharge of the report “World Precision Drugs Software program Trade” – https://www.reportlinker.com/p06032637/?utm_source=GNW
3 Billion within the 12 months 2020, is projected to succeed in a revised dimension of US$2.6 Billion by 2027, rising at aCAGR of 10.1% over the interval 2020-2027. On-Premise, one of many segments analyzed within the report, is projected to document 9.4% CAGR and attain US$1.5 Billion by the tip of the evaluation interval. After an early evaluation of the enterprise implications of the pandemic and its induced financial disaster, development within the Cloud phase is readjusted to a revised 11.1% CAGR for the following 7-year interval.
– The U.S. Market is Estimated at $352.1 Million, Whereas China is Forecast to Develop at 13.4% CAGR
– The Precision Drugs Software program market within the U.S. is estimated at US$352.1 Million within the 12 months 2020. China, the world`s second largest financial system, is forecast to succeed in a projected market dimension of US$537.8 Million by the 12 months 2027 trailing a CAGR of 13.2% over the evaluation interval 2020 to 2027. Among the many different noteworthy geographic markets are Japan and Canada, every forecast to develop at 7% and eight.7% respectively over the 2020-2027 interval. Inside Europe, Germany is forecast to develop at roughly 7.9% CAGR.

Choose Rivals (Whole 34 Featured) –

  • 2bprecise, LLC

  • Material Genomics, Inc.

  • Basis Drugs, Inc.

  • Gene42, Inc.

  • Human Longevity, Inc.

  • Lifeomic Well being, LLC

  • N-Of-One, Inc. (A Subsidiary of Qiagen N.V.)

  • Pieriandx, Inc.

  • Sophia Genetics Sa

  • Sunquest Data Methods, Inc.

  • Syapse, Inc.

  • Translational Software program Inc.

Learn the complete report: https://www.reportlinker.com/p06032637/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Influence of Covid-19 and a Looming World Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Desk 1: World Present & Future Evaluation for Precision Drugs
Software program by Geographic Area – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Center East and Africa
Markets – Unbiased Evaluation of Annual Gross sales in US$ Thousand
for Years 2020 by way of 2027 and % CAGR

Desk 2: World Historic Evaluate for Precision Drugs Software program
by Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 3: World 15-12 months Perspective for Precision Drugs
Software program by Geographic Area – Share Breakdown of Worth
Gross sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Center East and Africa Markets for Years 2012,
2020 & 2027

Desk 4: World Present & Future Evaluation for On-Premise by
Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2020 by way of 2027 and % CAGR

Desk 5: World Historic Evaluate for On-Premise by Geographic
Area – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Center East and Africa Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 6: World 15-12 months Perspective for On-Premise by Geographic
Area – Share Breakdown of Worth Gross sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Center East
and Africa for Years 2012, 2020 & 2027

Desk 7: World Present & Future Evaluation for Cloud by
Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2020 by way of 2027 and % CAGR

Desk 8: World Historic Evaluate for Cloud by Geographic Area –
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Center East and Africa Markets – Unbiased Evaluation of Annual
Gross sales in US$ Thousand for Years 2012 by way of 2019 and % CAGR

Desk 9: World 15-12 months Perspective for Cloud by Geographic
Area – Share Breakdown of Worth Gross sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Center East
and Africa for Years 2012, 2020 & 2027

Desk 10: World Present & Future Evaluation for Different Finish-Makes use of by
Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2020 by way of 2027 and % CAGR

Desk 11: World Historic Evaluate for Different Finish-Makes use of by
Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 12: World 15-12 months Perspective for Different Finish-Makes use of by
Geographic Area – Share Breakdown of Worth Gross sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Center East and Africa for Years 2012, 2020 & 2027

Desk 13: World Present & Future Evaluation for Healthcare
Suppliers by Geographic Area – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Center East and Africa
Markets – Unbiased Evaluation of Annual Gross sales in US$ Thousand
for Years 2020 by way of 2027 and % CAGR

Desk 14: World Historic Evaluate for Healthcare Suppliers by
Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 15: World 15-12 months Perspective for Healthcare Suppliers by
Geographic Area – Share Breakdown of Worth Gross sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Center East and Africa for Years 2012, 2020 & 2027

Desk 16: World Present & Future Evaluation for Analysis Facilities &
Tutorial Institutes by Geographic Area – USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Center East
and Africa Markets – Unbiased Evaluation of Annual Gross sales in
US$ Thousand for Years 2020 by way of 2027 and % CAGR

Desk 17: World Historic Evaluate for Analysis Facilities & Tutorial
Institutes by Geographic Area – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Center East and Africa
Markets – Unbiased Evaluation of Annual Gross sales in US$ Thousand
for Years 2012 by way of 2019 and % CAGR

Desk 18: World 15-12 months Perspective for Analysis Facilities &
Tutorial Institutes by Geographic Area – Share Breakdown
of Worth Gross sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa for Years
2012, 2020 & 2027

Desk 19: World Present & Future Evaluation for Pharma & Biotech
Firms by Geographic Area – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Center East and Africa
Markets – Unbiased Evaluation of Annual Gross sales in US$ Thousand
for Years 2020 by way of 2027 and % CAGR

Desk 20: World Historic Evaluate for Pharma & Biotech Firms
by Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 21: World 15-12 months Perspective for Pharma & Biotech
Firms by Geographic Area – Share Breakdown of Worth
Gross sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Center East and Africa for Years 2012, 2020 &
2027

Desk 22: World Present & Future Evaluation for Oncology by
Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2020 by way of 2027 and % CAGR

Desk 23: World Historic Evaluate for Oncology by Geographic
Area – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Center East and Africa Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 24: World 15-12 months Perspective for Oncology by Geographic
Area – Share Breakdown of Worth Gross sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Center East
and Africa for Years 2012, 2020 & 2027

Desk 25: World Present & Future Evaluation for Pharmacogenomics
by Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2020 by way of 2027 and % CAGR

Desk 26: World Historic Evaluate for Pharmacogenomics by
Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 27: World 15-12 months Perspective for Pharmacogenomics by
Geographic Area – Share Breakdown of Worth Gross sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Center East and Africa for Years 2012, 2020 & 2027

Desk 28: World Present & Future Evaluation for Uncommon Illnesses by
Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2020 by way of 2027 and % CAGR

Desk 29: World Historic Evaluate for Uncommon Illnesses by Geographic
Area – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Center East and Africa Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 30: World 15-12 months Perspective for Uncommon Illnesses by
Geographic Area – Share Breakdown of Worth Gross sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Center East and Africa for Years 2012, 2020 & 2027

Desk 31: World Present & Future Evaluation for Different
Functions by Geographic Area – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Center East and Africa
Markets – Unbiased Evaluation of Annual Gross sales in US$ Thousand
for Years 2020 by way of 2027 and % CAGR

Desk 32: World Historic Evaluate for Different Functions by
Geographic Area – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Center East and Africa Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 33: World 15-12 months Perspective for Different Functions by
Geographic Area – Share Breakdown of Worth Gross sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Center East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Desk 34: USA Present & Future Evaluation for Precision Drugs
Software program by Deployment – On-Premise and Cloud – Unbiased
Evaluation of Annual Gross sales in US$ Thousand for the Years 2020
by way of 2027 and % CAGR

Desk 35: USA Historic Evaluate for Precision Drugs Software program
by Deployment – On-Premise and Cloud Markets – Unbiased
Evaluation of Annual Gross sales in US$ Thousand for Years 2012 by way of
2019 and % CAGR

Desk 36: USA 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 37: USA Present & Future Evaluation for Precision Drugs
Software program by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers,
Analysis Facilities & Tutorial Institutes and Pharma & Biotech
Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 38: USA Historic Evaluate for Precision Drugs Software program
by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers, Analysis
Facilities & Tutorial Institutes and Pharma & Biotech Firms
Markets – Unbiased Evaluation of Annual Gross sales in US$ Thousand
for Years 2012 by way of 2019 and % CAGR

Desk 39: USA 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 40: USA Present & Future Evaluation for Precision Drugs
Software program by Utility – Oncology, Pharmacogenomics, Uncommon
Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 41: USA Historic Evaluate for Precision Drugs Software program
by Utility – Oncology, Pharmacogenomics, Uncommon Illnesses and
Different Functions Markets – Unbiased Evaluation of Annual
Gross sales in US$ Thousand for Years 2012 by way of 2019 and % CAGR

Desk 42: USA 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

CANADA
Desk 43: Canada Present & Future Evaluation for Precision
Drugs Software program by Deployment – On-Premise and Cloud –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for the
Years 2020 by way of 2027 and % CAGR

Desk 44: Canada Historic Evaluate for Precision Drugs
Software program by Deployment – On-Premise and Cloud Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 45: Canada 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 46: Canada Present & Future Evaluation for Precision
Drugs Software program by Finish-Use – Different Finish-Makes use of, Healthcare
Suppliers, Analysis Facilities & Tutorial Institutes and Pharma &
Biotech Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 47: Canada Historic Evaluate for Precision Drugs
Software program by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers,
Analysis Facilities & Tutorial Institutes and Pharma & Biotech
Firms Markets – Unbiased Evaluation of Annual Gross sales in US$
Thousand for Years 2012 by way of 2019 and % CAGR

Desk 48: Canada 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 49: Canada Present & Future Evaluation for Precision
Drugs Software program by Utility – Oncology, Pharmacogenomics,
Uncommon Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 50: Canada Historic Evaluate for Precision Drugs
Software program by Utility – Oncology, Pharmacogenomics, Uncommon
Illnesses and Different Functions Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 51: Canada 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

JAPAN
Desk 52: Japan Present & Future Evaluation for Precision
Drugs Software program by Deployment – On-Premise and Cloud –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for the
Years 2020 by way of 2027 and % CAGR

Desk 53: Japan Historic Evaluate for Precision Drugs Software program
by Deployment – On-Premise and Cloud Markets – Unbiased
Evaluation of Annual Gross sales in US$ Thousand for Years 2012 by way of
2019 and % CAGR

Desk 54: Japan 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 55: Japan Present & Future Evaluation for Precision
Drugs Software program by Finish-Use – Different Finish-Makes use of, Healthcare
Suppliers, Analysis Facilities & Tutorial Institutes and Pharma &
Biotech Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 56: Japan Historic Evaluate for Precision Drugs Software program
by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers, Analysis
Facilities & Tutorial Institutes and Pharma & Biotech Firms
Markets – Unbiased Evaluation of Annual Gross sales in US$ Thousand
for Years 2012 by way of 2019 and % CAGR

Desk 57: Japan 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 58: Japan Present & Future Evaluation for Precision
Drugs Software program by Utility – Oncology, Pharmacogenomics,
Uncommon Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 59: Japan Historic Evaluate for Precision Drugs Software program
by Utility – Oncology, Pharmacogenomics, Uncommon Illnesses and
Different Functions Markets – Unbiased Evaluation of Annual
Gross sales in US$ Thousand for Years 2012 by way of 2019 and % CAGR

Desk 60: Japan 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

CHINA
Desk 61: China Present & Future Evaluation for Precision
Drugs Software program by Deployment – On-Premise and Cloud –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for the
Years 2020 by way of 2027 and % CAGR

Desk 62: China Historic Evaluate for Precision Drugs Software program
by Deployment – On-Premise and Cloud Markets – Unbiased
Evaluation of Annual Gross sales in US$ Thousand for Years 2012 by way of
2019 and % CAGR

Desk 63: China 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 64: China Present & Future Evaluation for Precision
Drugs Software program by Finish-Use – Different Finish-Makes use of, Healthcare
Suppliers, Analysis Facilities & Tutorial Institutes and Pharma &
Biotech Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 65: China Historic Evaluate for Precision Drugs Software program
by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers, Analysis
Facilities & Tutorial Institutes and Pharma & Biotech Firms
Markets – Unbiased Evaluation of Annual Gross sales in US$ Thousand
for Years 2012 by way of 2019 and % CAGR

Desk 66: China 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 67: China Present & Future Evaluation for Precision
Drugs Software program by Utility – Oncology, Pharmacogenomics,
Uncommon Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 68: China Historic Evaluate for Precision Drugs Software program
by Utility – Oncology, Pharmacogenomics, Uncommon Illnesses and
Different Functions Markets – Unbiased Evaluation of Annual
Gross sales in US$ Thousand for Years 2012 by way of 2019 and % CAGR

Desk 69: China 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

EUROPE
Desk 70: Europe Present & Future Evaluation for Precision
Drugs Software program by Geographic Area – France, Germany,
Italy, UK, Spain, Russia and Remainder of Europe Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2020 by way of 2027 and % CAGR

Desk 71: Europe Historic Evaluate for Precision Drugs
Software program by Geographic Area – France, Germany, Italy, UK,
Spain, Russia and Remainder of Europe Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 72: Europe 15-12 months Perspective for Precision Drugs
Software program by Geographic Area – Share Breakdown of Worth
Gross sales for France, Germany, Italy, UK, Spain, Russia and Remainder of
Europe Markets for Years 2012, 2020 & 2027

Desk 73: Europe Present & Future Evaluation for Precision
Drugs Software program by Deployment – On-Premise and Cloud –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for the
Years 2020 by way of 2027 and % CAGR

Desk 74: Europe Historic Evaluate for Precision Drugs
Software program by Deployment – On-Premise and Cloud Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 75: Europe 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 76: Europe Present & Future Evaluation for Precision
Drugs Software program by Finish-Use – Different Finish-Makes use of, Healthcare
Suppliers, Analysis Facilities & Tutorial Institutes and Pharma &
Biotech Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 77: Europe Historic Evaluate for Precision Drugs
Software program by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers,
Analysis Facilities & Tutorial Institutes and Pharma & Biotech
Firms Markets – Unbiased Evaluation of Annual Gross sales in US$
Thousand for Years 2012 by way of 2019 and % CAGR

Desk 78: Europe 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 79: Europe Present & Future Evaluation for Precision
Drugs Software program by Utility – Oncology, Pharmacogenomics,
Uncommon Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 80: Europe Historic Evaluate for Precision Drugs
Software program by Utility – Oncology, Pharmacogenomics, Uncommon
Illnesses and Different Functions Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 81: Europe 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

FRANCE
Desk 82: France Present & Future Evaluation for Precision
Drugs Software program by Deployment – On-Premise and Cloud –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for the
Years 2020 by way of 2027 and % CAGR

Desk 83: France Historic Evaluate for Precision Drugs
Software program by Deployment – On-Premise and Cloud Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 84: France 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 85: France Present & Future Evaluation for Precision
Drugs Software program by Finish-Use – Different Finish-Makes use of, Healthcare
Suppliers, Analysis Facilities & Tutorial Institutes and Pharma &
Biotech Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 86: France Historic Evaluate for Precision Drugs
Software program by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers,
Analysis Facilities & Tutorial Institutes and Pharma & Biotech
Firms Markets – Unbiased Evaluation of Annual Gross sales in US$
Thousand for Years 2012 by way of 2019 and % CAGR

Desk 87: France 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 88: France Present & Future Evaluation for Precision
Drugs Software program by Utility – Oncology, Pharmacogenomics,
Uncommon Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 89: France Historic Evaluate for Precision Drugs
Software program by Utility – Oncology, Pharmacogenomics, Uncommon
Illnesses and Different Functions Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 90: France 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

GERMANY
Desk 91: Germany Present & Future Evaluation for Precision
Drugs Software program by Deployment – On-Premise and Cloud –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for the
Years 2020 by way of 2027 and % CAGR

Desk 92: Germany Historic Evaluate for Precision Drugs
Software program by Deployment – On-Premise and Cloud Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 93: Germany 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 94: Germany Present & Future Evaluation for Precision
Drugs Software program by Finish-Use – Different Finish-Makes use of, Healthcare
Suppliers, Analysis Facilities & Tutorial Institutes and Pharma &
Biotech Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 95: Germany Historic Evaluate for Precision Drugs
Software program by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers,
Analysis Facilities & Tutorial Institutes and Pharma & Biotech
Firms Markets – Unbiased Evaluation of Annual Gross sales in US$
Thousand for Years 2012 by way of 2019 and % CAGR

Desk 96: Germany 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 97: Germany Present & Future Evaluation for Precision
Drugs Software program by Utility – Oncology, Pharmacogenomics,
Uncommon Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 98: Germany Historic Evaluate for Precision Drugs
Software program by Utility – Oncology, Pharmacogenomics, Uncommon
Illnesses and Different Functions Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 99: Germany 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

ITALY
Desk 100: Italy Present & Future Evaluation for Precision
Drugs Software program by Deployment – On-Premise and Cloud –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for the
Years 2020 by way of 2027 and % CAGR

Desk 101: Italy Historic Evaluate for Precision Drugs
Software program by Deployment – On-Premise and Cloud Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 102: Italy 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 103: Italy Present & Future Evaluation for Precision
Drugs Software program by Finish-Use – Different Finish-Makes use of, Healthcare
Suppliers, Analysis Facilities & Tutorial Institutes and Pharma &
Biotech Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 104: Italy Historic Evaluate for Precision Drugs
Software program by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers,
Analysis Facilities & Tutorial Institutes and Pharma & Biotech
Firms Markets – Unbiased Evaluation of Annual Gross sales in US$
Thousand for Years 2012 by way of 2019 and % CAGR

Desk 105: Italy 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 106: Italy Present & Future Evaluation for Precision
Drugs Software program by Utility – Oncology, Pharmacogenomics,
Uncommon Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 107: Italy Historic Evaluate for Precision Drugs
Software program by Utility – Oncology, Pharmacogenomics, Uncommon
Illnesses and Different Functions Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 108: Italy 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

UNITED KINGDOM
Desk 109: UK Present & Future Evaluation for Precision Drugs
Software program by Deployment – On-Premise and Cloud – Unbiased
Evaluation of Annual Gross sales in US$ Thousand for the Years 2020
by way of 2027 and % CAGR

Desk 110: UK Historic Evaluate for Precision Drugs Software program
by Deployment – On-Premise and Cloud Markets – Unbiased
Evaluation of Annual Gross sales in US$ Thousand for Years 2012 by way of
2019 and % CAGR

Desk 111: UK 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 112: UK Present & Future Evaluation for Precision Drugs
Software program by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers,
Analysis Facilities & Tutorial Institutes and Pharma & Biotech
Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 113: UK Historic Evaluate for Precision Drugs Software program
by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers, Analysis
Facilities & Tutorial Institutes and Pharma & Biotech Firms
Markets – Unbiased Evaluation of Annual Gross sales in US$ Thousand
for Years 2012 by way of 2019 and % CAGR

Desk 114: UK 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 115: UK Present & Future Evaluation for Precision Drugs
Software program by Utility – Oncology, Pharmacogenomics, Uncommon
Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 116: UK Historic Evaluate for Precision Drugs Software program
by Utility – Oncology, Pharmacogenomics, Uncommon Illnesses and
Different Functions Markets – Unbiased Evaluation of Annual
Gross sales in US$ Thousand for Years 2012 by way of 2019 and % CAGR

Desk 117: UK 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

SPAIN
Desk 118: Spain Present & Future Evaluation for Precision
Drugs Software program by Deployment – On-Premise and Cloud –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for the
Years 2020 by way of 2027 and % CAGR

Desk 119: Spain Historic Evaluate for Precision Drugs
Software program by Deployment – On-Premise and Cloud Markets –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for Years
2012 by way of 2019 and % CAGR

Desk 120: Spain 15-12 months Perspective for Precision Drugs
Software program by Deployment – Share Breakdown of Worth Gross sales
for On-Premise and Cloud for the Years 2012, 2020 & 2027

Desk 121: Spain Present & Future Evaluation for Precision
Drugs Software program by Finish-Use – Different Finish-Makes use of, Healthcare
Suppliers, Analysis Facilities & Tutorial Institutes and Pharma &
Biotech Firms – Unbiased Evaluation of Annual Gross sales in US$
Thousand for the Years 2020 by way of 2027 and % CAGR

Desk 122: Spain Historic Evaluate for Precision Drugs
Software program by Finish-Use – Different Finish-Makes use of, Healthcare Suppliers,
Analysis Facilities & Tutorial Institutes and Pharma & Biotech
Firms Markets – Unbiased Evaluation of Annual Gross sales in US$
Thousand for Years 2012 by way of 2019 and % CAGR

Desk 123: Spain 15-12 months Perspective for Precision Drugs
Software program by Finish-Use – Share Breakdown of Worth Gross sales for
Different Finish-Makes use of, Healthcare Suppliers, Analysis Facilities &
Tutorial Institutes and Pharma & Biotech Firms for the
Years 2012, 2020 & 2027

Desk 124: Spain Present & Future Evaluation for Precision
Drugs Software program by Utility – Oncology, Pharmacogenomics,
Uncommon Illnesses and Different Functions – Unbiased Evaluation of
Annual Gross sales in US$ Thousand for the Years 2020 by way of 2027
and % CAGR

Desk 125: Spain Historic Evaluate for Precision Drugs
Software program by Utility – Oncology, Pharmacogenomics, Uncommon
Illnesses and Different Functions Markets – Unbiased Evaluation
of Annual Gross sales in US$ Thousand for Years 2012 by way of 2019 and
% CAGR

Desk 126: Spain 15-12 months Perspective for Precision Drugs
Software program by Utility – Share Breakdown of Worth Gross sales
for Oncology, Pharmacogenomics, Uncommon Illnesses and Different
Functions for the Years 2012, 2020 & 2027

RUSSIA
Desk 127: Russia Present & Future Evaluation for Precision
Drugs Software program by Deployment – On-Premise and Cloud –
Unbiased Evaluation of Annual Gross sales in US$ Thousand for the
Years 2020 by way of 2027 and % CAGR

Please contact our Buyer Help Middle to get the whole Desk of Contents
Learn the complete report: https://www.reportlinker.com/p06032637/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market analysis answer. Reportlinker finds and organizes the newest business information so that you get all of the market analysis you want – immediately, in a single place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Related posts

Oakland County’s luxurious dwelling market booming

admin

Indices snap 2-day shedding run, Sensex ends 359 pts up; Bajaj twins lead

admin

International Knowledge Middle Automation Software program Market (2020 to 2024)

admin

Leave a Comment